On June 3, 2017, TG Therapeutics, Inc. (the “Company”) issued a press release announcing positive results from its Phase 3 GENUINE trial of TG-1101 (ublituximab) plus ibrutinib in patients with previously treated high risk Chronic Lymphocytic Leukemia (CLL) presented in an oral session during the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. On June 5, 2017, the Company announced updated clinical data from its ongoing Phase I/Ib trial of TG-1101 (ublituximab) in combination with TGR-1202 (umbralisib) in patients with CLL and Non-Hodgkin’s Lymphoma (NHL) presented during the 53rd ASCO Annual Meeting. Copies of the press releases are being filed as Exhibits 99.1 and 99.2 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated June 3, 2017.

99.2 Press Release, dated June 5, 2017.

About TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.